France remains a cornerstone of the European pharmaceutical industry, ranking among the top three producers in the EU. With major hubs like the "BioValley" in Alsace and the "Cosmetic Valley" near Paris, the demand for high-quality Active Pharmaceutical Ingredients (APIs) and chemical intermediates has shifted from mere price-point competition to a focus on Supply Chain Sovereignty and Green Chemistry.
Jiangxi Serum Pharma Industries Co., Ltd. aligns with the France 2030 investment plan, providing French manufacturers with the resilient sourcing needed to mitigate global volatility. Our expertise spans nearly a decade, bridging the gap between high-capacity Chinese manufacturing and the stringent regulatory requirements of the ANSM (National Agency for the Safety of Medicines and Health Products).
Est. in Serum Pharma
Global Strategic Partners
Annual Export Value
GMP & ISO Compliance
Leading the transition to Pharma 4.0 through advanced chemical and biological synthesis.
Transitioning from batch to continuous processes to ensure higher purity profiles and lower environmental footprints for French industrial clients.
Leveraging enzymatic synthesis to produce complex intermediates like NMN and CoQ10 with pharmaceutical-grade consistency.
Customized solubility enhancement for biological products, ensuring maximum bioavailability in final formulations.
In an era of rising energy costs in Europe, Jiangxi Serum Pharma offers a strategic cost advantage without compromising on quality. Our "Factory 4.0" initiative integrates:
Our facility acts as a High-Volume Hub for vaccines, western medicines, and plant-derived raw materials, serving as a reliable secondary or primary source for French procurement directors.
We provide full dossier support (DMF, CEP) and ensure all chemical intermediates are REACH registered for the French market. Our local support ensures that customs clearance and regulatory audits are seamless.
Through our established logistics network, we offer flexible shipping solutions to French ports (Le Havre, Marseille), reducing lead times and allowing French companies to maintain lean inventory levels.
We maintain rigorous internal quality control systems that align with EU-GMP standards. All pharmaceutical products and intermediates undergo multi-stage validation, and we provide complete documentation (COA, MSDS, and technical dossiers) to satisfy French regulatory audits.
For standard stock APIs and nutritional ingredients, air freight to Paris (CDG) or Lyon (LYS) takes 7-10 business days. Sea freight for bulk intermediates typically ranges from 30-35 days, arriving at the ports of Le Havre or Marseille.
Yes. Our R&D team specializes in "Pre-Mix" and "Bio-Fermentation" customization. We work under strict non-disclosure agreements (NDAs) to support French biotech firms in their early-stage intermediate synthesis and scale-up phases.
Environment, Social, and Governance (ESG) criteria are integrated into our 4.0 factory design. We focus on continuous flow chemistry to reduce solvent use and maintain high social welfare standards for our technical workforce, aligning with the ethical sourcing policies of top-tier French firms.
